Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma
- Focus Adverse reactions
- 21 Sep 2019 Planned End Date changed from 3 Jul 2022 to 12 Mar 2023.
- 21 Sep 2019 Planned primary completion date changed from 3 Jul 2021 to 12 Mar 2022.
- 18 Jul 2018 New trial record